Universal Ibogaine CEO Nick Karos joined Steve Darling from Proactive to share news the company has entered into an agreement with Psygen Labs to secure a supply of GMP ibogaine for use in its planned future clinical trial for opioid use disorder and ongoing ibogaine detox treatments at its clinics. Karos telling Proactive, this agreement covers basic terms as to pricing, manufacture, and delivery of ibogaine that will be required, based on the ultimate size of the patient group required for the planned clinical trials.
Universal Ibogaine takes big step forward entering into drug supply agreement
